Search

Your search keyword '"Unité de génétique somatique"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Unité de génétique somatique" Remove constraint Author: "Unité de génétique somatique"
136 results on '"Unité de génétique somatique"'

Search Results

1. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility

2. Chimeric oncogene regulates the EGR2 sarcoma susceptibility gene via a GGAA-microsatellite

3. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

4. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA

5. Brain tumor with an ATXN1-NUTM1 fusion gene expands the histologic spectrum of NUTM1-rearranged neoplasia

6. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors

7. SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation

8. Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production

9. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses

10. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling

11. PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis

12. Transcriptomic definition of molecular subgroups of small round cell sarcomas

13. NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma

14. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response

15. Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-fused Sarcomas

16. Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor

17. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries

18. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model

19. Detection of tumor ALK status in neuroblastoma patients using peripheral blood

20. Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort

21. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis

22. Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC- Abolishes Ewing Sarcoma Growth in vivo

23. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion

24. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma

25. Overall genomic pattern is a predictor of outcome in neuroblastoma

26. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas

27. Two types of chromosome 1p losses with opposite significance in gliomas

28. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

29. Impact of age on survival according to molecular tumor findings in children and adolescents with soft-tissue and bone sarcoma: The BIOSCA project.

30. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.

31. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.

32. Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors.

33. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.

34. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

35. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.

36. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding.

37. VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis.

38. Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.

39. Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions.

41. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.

42. Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents.

43. An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABA A receptor.

44. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.

45. Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

46. STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma.

47. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.

49. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.

50. Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer.

Catalog

Books, media, physical & digital resources